How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive

A Poggi, S Varesano, MR Zocchi

Research output: Contribution to journalArticle

Abstract

Experimental evidence indicates that mesenchymal stromal cells (MSCs) may regulate tumor microenvironment (TME). It is conceivable that the interaction with MSC can influence neoplastic cell functional behavior, remodeling TME and generating a tumor cell niche that supports tissue neovascularization, tumor invasion and metastasization. In addition, MSC can release transforming growth factor-beta that is involved in the epithelial-mesenchymal transition of carcinoma cells; this transition is essential to give rise to aggressive tumor cells and favor cancer progression. Also, MSC can both affect the anti-tumor immune response and limit drug availability surrounding tumor cells, thus creating a sort of barrier. This mechanism, in principle, should limit tumor expansion but, on the contrary, often leads to the impairment of the immune system-mediated recognition of tumor cells. Furthermore, the cross-talk between MSC and anti-tumor lymphocytes of the innate and adaptive arms of the immune system strongly drives TME to become immunosuppressive. Indeed, MSC can trigger the generation of several types of regulatory cells which block immune response and eventually impair the elimination of tumor cells. Based on these considerations, it should be possible to favor the anti-tumor immune response acting on TME. First, we will review the molecular mechanisms involved in MSC-mediated regulation of immune response. Second, we will focus on the experimental data supporting that it is possible to convert TME from immunosuppressive to immunostimulant, specifically targeting MSC. © 2018 Poggi, Varesano and Zocchi.
Original languageEnglish
Article number262
JournalFrontiers in Immunology
Volume9
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive'. Together they form a unique fingerprint.

  • Cite this